drugset / Trial / NCT01439789
Study of Efficacy on NT-proBNP of Recombinant Human Neuregulin-1 in Chronic Heart Failure Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multi-center, randomized, double-blind , placebo parallel controlled, standard therapy based phase III clinical trial, to evaluate the efficacy of recombinant human neuregulin-1 on serum NT-proBNP, as well as safety in patients with chronic heart failure.
Timeline
- Start
- 2011-06
- Primary completion
- 2012-06
- Completion
- 2012-06
Outcome
Outcome not reported
Stopped: “Sponsor has designed another study with different endpoint to replace the current study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Protein / enzyme biologic | 0.6 ug/kg | Intravenous |